
Zenas BioPharma, Inc.: updates and filings
Price
$23.85
November 20, 2026Market cap $1.6B
What Ploutos Investor adds for Zenas BioPharma
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
August 2026
May 2026
March 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 6, 2026Other material eventsForm8-K
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Oct 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 13, 2026Regulation FD disclosureForm8-K
- Sep 11, 2026Shelf registration for future offeringsFormS-3ASR
- Sep 11, 2026Shares registered for employeesFormS-8
- Sep 8, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Sep 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 19, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 17, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operations, officer or director changeForm8-K
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operations, officer or director change, shareholder voteForm8-K
- May 5, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Apr 2, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Mar 31, 2026Material agreement entered, new material financial obligation, other material eventsForm8-K
- Mar 16, 2026Additional annual meeting materialFormDEFA14A
- Mar 16, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Mar 16, 2026Annual meeting proxy statementFormDEF 14A
- Mar 16, 2026Shares registered for employeesFormS-8
- Mar 16, 2026Annual reportfor the period to Dec 31, 2025Form10-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 6, 2026 | 8-K | Other material events | Document |
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Oct 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 13, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 11, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Sep 11, 2026 | S-8 | Shares registered for employees | Document |
| Sep 8, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Sep 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 19, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 17, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations, officer or director change | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations, officer or director change, shareholder vote | Document |
| May 5, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Apr 2, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Mar 31, 2026 | 8-K | Material agreement entered, new material financial obligation, other material events | Document |
| Mar 16, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 16, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Mar 16, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 16, 2026 | S-8 | Shares registered for employees | Document |
| Mar 16, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 15, 2022.
The full analysis
What do Zenas BioPharma's filings show?
The filings are where every one of Zenas BioPharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.